Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Colon Inflammation, Iron Malabsorption, Obesity, Diet Modification
Interventions: High heme iron diet, Low iron diet, Plant-based high non-heme iron diet; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 55 Years to 70 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Iron Deficiency Anaemia
Interventions: iron isomaltoside 1000 (Monofer®), iron sucrose (Venofer®); Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Iron Deficiency
Interventions: Iron sucrose; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: THALASSEMIA MAJOR
Interventions: Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 12 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Hookworm Infection, Hookworm Disease
Interventions: 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel, 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg), 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg); Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer, Bladder Cancer, Kidney Cancer
Interventions: Ferumoxytol, Magnetic Resonance Imaging (MRI); Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia in Pregnancy
Interventions: Placebo, Ferrous Sulfate; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Iron-deficiency, Iron Deficiency Anemia, Iron Deficiency Anemia Treatment
Interventions: FeSO4, Ao iron; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
Interventions: 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, MRI-Based Angiogram; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anemia
Interventions: ferumoxytol, moxifloxacin, placebo; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Interventions: Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine; Drug · Diagnostic Test
Lead sponsor: University of Utah; Other
Eligibility: 35 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions: Nicardipine and Nipride; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Oakland, California + 20 more

Conditions: Anemia, Iron Deficiency
Interventions: Oral iron supplementation; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Anemia, Iron Deficiency
Interventions: Intrinsic Hepcidin IDx™ Test; Diagnostic Test
Lead sponsor: Intrinsic LifeSciences, LLC; Industry
Eligibility: 11 Years and older
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions: SSP-004184AQ; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Oakland, California • Boston, Massachusetts

Conditions: Breast Cancer, Leukemia, Lymphoma
Interventions: HeartPhone app, Acetylcholine, Sodium Nitroprusside, L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester; Behavioral · Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Anemia, Hemosiderosis
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Oakland, California • Stanford, California • Boston, Massachusetts + 2 more

Conditions: Pregnancy Related, Iron Deficiency Anemia of Pregnancy
Interventions: Ferrous sulfate; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Interventions: blood donation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Very Low Birth Weight Infants
Interventions: Lactoferrin; Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: Up to 14 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Charlottesville, Virginia

Conditions: Anemia of Prematurity, Very Low Birth Weight Infant
Interventions: 2mg/kg/day Iron Sulfate, 6 mg/kg/day Iron Sulfate; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 1 Day to 6 Months
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hemorrhage, Anemia
Interventions: Ferrous sulfate, Capsule Endoscopy; Dietary Supplement · Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Transfusional Iron Overload
Interventions: ICL670; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Oakland, California • Orange, California • Boston, Massachusetts + 4 more

Search by objective public record fields.

Obesity, Iron Regulation and Colorectal Cancer Risk

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

The Safety of a High-Dose, Rapid Infusion of Iron Sucrose

Reproductive Capacity and Iron Burden in Thalassemia

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Once Versus Twice Daily Iron Supplementation in Pregnant Women

Effect of Iron Source on the Growth of Enteric Pathogens

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

Novel Imaging Markers in SPMS

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Iron Supplement to Improve Iron Status Following Bariatric Surgery

Serum Hepcidin Immunoassay - Laboratory to Marketplace

Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

HeartPhone Cancer Survivors Trial 2019

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy

Iron Depletion Therapy for Type 2 DM and NAFLD

Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants

Iron Supplementation and Intestinal Health

Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity